The Genomic Atlas of Breast Cancer — the non-coding theme

Update News

  • GABC update 2020.06.15
  • GABC update 2019.03.20
  • GABC online 2018.08.09
  • Data collection 2018.04.09

About Us

  • Steven Xi Chen:
    steven.chen@miami.edu
  • Yunpeng Zhang:
    YXZ1418@med.miami.edu
  • Peng Wang:
    wpgqy@163.com
  • Shangwei Ning:
    ningsw@ems.hrbmu.edu.cn
  • Xia Li:
    lixia@hrbmu.edu.cn

Detail


Chr NA
start NA
end NA
ID NA
miRNA_name hsa-miR-105
methods qRT-PCR,etc
regulated up
Function Description Results:Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastaticversus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like(p= 0.037) and in luminal B versus luminal A (p= 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlatedwith clinical and pathological variables such as progesterone receptor status (p= 0.017) and Ki67 (p= 0.05). Duringneoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p= 0.039) andinversely with Ki67 expression (p= 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155were significantly associated with the presence of circulating tumor cells.Conclusion:Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementaryclinical tool for improving breast cancer diagnosis and prognosis
PMID 30728048
year 2019
Title Exosomal miRNA profile as complementarytool in the diagnostic and prediction oftreatment response in localized breastcancer under neoadjuvant chemotherapy
drug X
circulating V
survival X

CopyRight © University of Miami, USA; Harbin Medical University, China